The introduction of effective antiretroviral therapy (ART) has transformed HIV infection from a deadly to a chronic infection. Despite its successes in reducing mortality, ART fails to cure HIV allowing HIV to persist in vivo. HIV persistence under ART is thought to be mediated by a combination of latent infection of long-lived cells, homeostatic proliferation of latently infected cells, anatomic sanctuaries, and low-level virus replication. To understand the contribution of specific cell types and anatomic sites to virus persistence in vivo animal models are necessary.
INTRODUCTION
Antiretroviral therapy (ART) has transformed HIV into a life-long chronic infection. However, ART has failed to provide a cure for HIV as virus replication rapidly rebounds if ART is interrupted. Additionally, life-long ART does not fully reverse the immunological abnormalities associated with HIV infection resulting in drug toxicities and creates a massive financial burden for healthcare systems worldwide. The major barrier to HIV cure is the persistence of latently infected long-lived CD4 þ memory T cells, where latent infection is defined as the presence of stably integrated HIV DNA in absence of active viral production. The study of HIV persistence is limited because of the rarity of latent cells in vivo that harbor replication competent virus, estimated to be $1 per million memory CD4 þ T cells, and difficulty in accurately modeling HIV latency and persistence in vitro. In addition, HIV persistence is a very complex virological and immunological phenomenon, with infection of several cell types in a wide array of anatomic tissues that are all regulated differently. These include various subsets of CD4 þ T cells, such as central memory T cells (T CM ), follicular helper T cells (T FH ), T memory stem cells (T SCM ), and regulatory T cells (T REG ) in blood and lymphoid tissues, effector memory T cells (T EM ) and T helper-17 cells (T H17 ) in the gut, microglial cells and astrocytes in the central nervous system and, more controversially, monocytes, macrophages and dendritic cells [1-4,5 && ]. Therefore, a cure to HIV persistence will likely require a combination of several virus elimination strategies, similar to combination ART or poly-chemotherapy for cancer, to eliminate the different components of the virus reservoir in different tissues and cells. Nonhuman primate (NHP) models using Indian rhesus macaques (RM; Macaca mulatta) or pigtail macaques (PTM, Macaca nemestrina) experimentally infected with simian immunodeficiency virus (SIV) or simian/HIV (SHIV) and treated with ART have similar pathogenesis and disease progression compared with ART-treated HIV infection in humans [6] [7] [8] . The study of HIV/ AIDS with NHP models has been instrumental in our current understanding of HIV pathogenesis, previously reviewed by Evans and Silvestri [9] . In this review, we will summarize the recent progress in the use of animal models to understand HIV persistence and test potential cure strategies.
ANIMAL MODELS FOR HIV PERSISTENCE
Historically, a key limitation of the SIV/RM model to study virus reservoirs has been the lack of optimized ART regimens that fully suppress virus replication. Today, newer ART combinations and formulations can be used in RM and PTM that are extremely effective in reducing plasma viral loads to levels equivalent to what is observed in HIV-1-infected patients on ART, thus providing an excellent in vivo model of HIV persistence [ ,15]. As summarized in Table 1 , there are many benefits to using NHP models in the study of HIV persistence, including the fact that they allow us to extensively sample tissues that are not readily accessible in humans, to study rare cell populations in tissues and blood, such as T SCM , T FH , and T-follicular regulatory cells (T FR ) [ SHIVs that are designed to include the HIV reverse transcriptase (RT) gene (to improve the susceptibility to certain reverse transcriptase inhibitors) or the HIV Env gene (for studies of the anti-reservoir effects of HIV-specific broadly neutralizing antibodies). These viruses are typically used at high concentrations to induce robust levels of infection with a single dose challenge. After establishment of infection, ART is administered orally or subcutaneously, with studies reporting ART initiation anywhere from day 3 to day 60 post infection (or later). The choice of the time of ART initiation should reflect that in HIV-infected humans delayed treatment initiation leads to a greater size of the HIV DNA reservoir [35] . ART formulations used in NHP have included two nucleoside reverse transcriptase inhibitors [typically tenofovir (PMPA; {[(2R)-1-(6amino-9H-purin-9-yl) propan-2-yl]oxy}methyl)phosphonic acid) and emtricitabine (FTC)], a protease inhibitor (often darunavir) and an integrase inhibitor (raltegravir or dolutegravir) with possible intensification with a chemokine receptor 5 (CCR5) inhibitor (maraviroc) or a non-nucleoside reverse transcriptase inhibitor in the case of RT-SHIV infection. Although ART formulations differ slightly in various published studies, all ART formulations are highly effective in reducing virus replication by several logs, commonly below detectable levels in plasma, as tested using different viral RNA assays (detection ranges from 3 to 100 copies/ml). After 6-12 months of virus suppression, which may take variable amounts of time (1-4 months), the cure or latency reversal strategy is tested. It should be noted that while an absolute recapitulation of long-term ART-treated HIV-infected individuals would suggest the use of prolonged ART in SIV/SHIV-infected macaques, logistical and financial considerations may in fact limit the length of treatment in these animals. We propose that 6-12 months of virus suppression is a reasonable approximation of ARTtreated patients that allows for more rapid evaluation of potential cure approaches. Finally, to test the efficacy of the used 'antireservoir' intervention the size of the viral reservoir can be measured directly using assays such as total and integrated cell-associated SIV-DNA ( [36] , Mavigner et al., unpublished), Tat-Rev-induced limiting dilution assay (TILDA; [37] ), and quantitative viral outgrowth assays (QVOA; [38, 39, 10, 34 && ] with input cells derived from blood or multiple tissues through biopsies or at necropsy (summarized in Table 2 ). An alternative study design involves the functional measurement of the virus reservoirs as inferred by the kinetics of virus rebound after ART interruption [11 & ,12 && ,14 && ]. Overall, these types of studies involving ART-treated SIV/SHIV-infected macaques are highly informative in the field of HIV cure research and their use has increased rapidly over the past few years. However, there are biological caveats and limitations to using NHP models for studies of HIV cure. These include the presence of species-specific differences in certain immune function (i.e., major-histocombatibility-complex (MHC) genes), as well as high costs associated with animal housing and care ( Table 1 ). As such, although these NHP models provide an excellent tool to study HIV persistence and potential therapeutic strategies that can be used to disrupt persistence, all key findings must ultimately be replicated in the setting of HIV infection of humans. The humanized mouse model provides a smallscale animal model to study HIV infection, and upon ART treatment mice control viremia and immune function recovers [40] [41] [42] . Given recent reviews of the humanized mouse models for use in HIV persistence by Policicchio et al. [43] and Garcia [44] here we will briefly describe two robust mouse models. The bone marrow-liver-thymus (BLT) mouse model is the best representative of a humanized mouse with latent HIV infection [45] , where irradiated non-obese diabetic (NOD)-SCIDtransgeneic mouse (NOD.CB17-Prkdc SCID/J; NSG) are transplanted with human bone marrow, liver, and thymus to repopulate with a humanized immune system, including T cells, B cells, monocytes, macrophages, and dendritic cells [46] . Infection progresses similar to humans and latency is established at a similar frequency, allowing potential HIV therapeutics to be tested [47] . To only assess T-cell function in HIV persistence, a humanized mouse model has been developed with engraftment of only human T cells and no myeloid cells, T cell only mouse (ToM), in a similar method to BLT engraftment [48] . Importantly, the ToM mice do not develop graft-versus-host disease, have potent HIV infection, which is suppressed by ART and rebounds with ART interruption. Additionally, latency is detected at a similar frequency to humans as measured by the QVOA [38] . The same group has also developed a model with myeloid cells and no lymphoid cells, myeloid cell only mouse (MoM; Honeycutt JCI, in press). The ToM and MoM models have allowed researchers to address important questions regarding virus persistence within T cells or myeloid cells only, allowing differentiation of their specific contribution to virus persistence. However, because of suboptimal human immune cell engraftment and the small size of mice the latent reservoir remains small and detection of rare immune cell populations, like T SCM and T FH cells, remains difficult. Furthermore, blood volumes obtained are limited leading to reduced ability to measure virus suppression below a threshold of 400 copies/ml [39] .
INSIGHTS FROM NONHUMAN PRIMATE MODELS OF SIV PERSISTENCE

Early establishment of latent infection
In a recent influential study Whitney et al.
[12 && ] investigated the early kinetics of reservoir establishment in RM infected with SIVmac251 and early initiation of ART at day 3, 7, 10, and 14 postinfection. Interestingly, the authors found that ART initiation at day 3 resulted in detectable SIV RNA and DNA in lymph nodes and colorectal mucosa, but neither SIV DNA in peripheral blood mononuclear cells (PBMCs) nor SIV RNA in plasma. In the animals initiated on ART at day 7, 10, and 14 post-infection, that is, after detection of plasma viremia, and viral RNA and DNA in PBMC, lymph nodes and colorectal mucosa, subsequent ART interruption resulted in rapid virus rebound within 7 days. Animals in which treatment was initiated before the presence of detectable SIV RNA in plasma (day 3 ART initiation), a delayed rebound (day 21 post-ART interruption) was observed. These data are consistent with human studies suggesting that early ART initiation leads to a smaller reservoir size and slower disease progression [35] . The findings by Whitney et al. highlight that a small but clearly fully functional SIV reservoir is established very early after experimental inoculation of SIV and before virus detection in plasma and PBMC, with latent virus infection of a critical mass of cells in lymphoid tissues. The implication of these findings for HIV infection in humans is that early ART initiation alone is highly unlikely to represent a potential cure for HIV, but may represent a setting in which additional interventions targeting the established but smaller reservoir are more likely to be effective.
Virus persistence in CD4 R memory stem T cells (T scm )
Despite an initial observation of HIV infection of hematopoietic stem cells in vitro [49] , most human studies suggest that hematopoietic stem cells do not contribute to the latent reservoir in vivo [50] . In contrast, multipotent CD4 þ , T SCM harbor high amounts of viral DNA and contribute to the latent reservoir in CD4 þ memory T cells; in fact, this contribution increases over time in long-term ART-treated HIV-infected humans [3] . In addition, studies from our lab of CD4 þ T SCM in SIV-infected RM in the absence of ART revealed that these cells are readily infected with SIV in both blood and lymphoid tissues [16 & ]. We found that whereas total T SCM numbers were maintained, the fraction CD4 þ T SCM expressing CCR5 was depleted while the percentage of CD4 þ T SCM expressing the proliferation antigen Ki-67 was expanded [16 & ]. In follow-up work, SIV-infected RM were treated with ART and we found that suppression of virus replication is associated with an improved homeostasis of the CD4 þ T SCM compartment but no major decline of the fraction of these cells containing SIV DNA, even though the frequency of the shorter-lived CD4 þ T TM and T EM harboring SIV DNA declined significantly under ART (Cartwright, unpublished data). Interestingly, Jaafoura et al. [51 && ] reached similar conclusions regarding the role of CD4 þ T SCM in virus persistence under ART by using mathematical modeling of integrated HIV DNA levels in CD4 þ T cell subsets from ART-treated patients. Collectively, these studies show that CD4 þ T SCM may be important contributors to life-long HIV/SIV persistence under ART, and further highlight the importance of targeting cure strategies toward elimination of latent infection in all long-lived cells.
The role of germinal centers and follicular T helper cells in viral persistence
The role of germinal centers and T FH in HIV persistence has been poorly studied until recently because of the lack of accurate in vivo models. Previous work has shown that human follicular dendritic cells (FDC) in germinal centers can harbor HIV on their surface in an archival fashion, where virus on these FDC persists for months without decay [52] [53] [54] [55] . Connick et al. [56] found that germinal centers harbor high levels of SIV RNA and proposed that poor CD8 þ T cell infiltration in the lymph node drives persistence of SIV RNA in germinal centers. Petrovas et al. . Although both T FH and T FR are known to be important in the development of a strong and balanced humoral response against HIV/SIV antigens during vaccination (and potentially therapeutic vaccination as part of a curative approach), these studies show that T FH and T FR infection are also important for HIV persistence in that they function as viral targets and represent a source of low-level viremia under ART [59] . Collectively, these observations suggest that virus-producing T FH in the B-cell area of lymph nodes form a continual source of virions that can bind to and interact with FDC, and in the context of limited CD8 þ T cell-mediated clearance and possibly low bio-distribution of drugs in lymph nodes, may crucially contribute to virus persistence under ART.
The role of CD8 R T cells in controlling viremia under antiretroviral therapy
It is well accepted that CD8 þ T cells control virus replication in vivo during the natural history of HIV and SIV infection. This evidence includes the key observation that in vivo depletion of CD8 þ lymphocytes in SIV-infected RM invariably results in increased levels of virus replication [60] [61] [62] . However, these earlier studies did not address the role of CD8 þ T cells in suppressing virus replication under ART treatment. Recently, we performed experimental CD8 þ lymphocyte depletion in 13 ART-treated, SIV-infected RM, and found that this procedure resulted in increased virus production in both plasma and lymphoid tissues in 13 out of 13 of the animals, with levels of viremia up to $5000 copies/ml from plasma, whereas ART was maintained (Cartwright, unpublished). In most animals, we also observed that upon CD8 þ T-cell repopulation (but not natural killer [NK] cell repopulation), viremia returned to an undetectable level. Taken together, these data indicate that CD8 þ lymphocytes are required to maintain virus suppression in ART-treated SIV-infected RM. Our data reveal a previously unrecognized antiviral function of CD8 þ lymphocytes that could be boosted by interventions such as therapeutic vaccination and immune-based interventions to release inhibitory stimuli from CD8 þ T cells (e.g., checkpoint blockade inhibitors; Cartwright, unpublished).
SIV CURE STRATEGIES
Total body irradiation, bone marrow transplant and hematopoietic stem cell engraftment in nonhuman primates
To date only one person, the Berlin patient, appears to have been cured of HIV. This patient was treated for acute myeloid lymphoma with two rounds of total body irradiation (TBI) followed by bone marrow transplant (BMT) with an HIV resistant, homozygous CCR5D32 donor [63, 64] . Follow-up studies have failed to achieve a similar outcome in two HIV-infected individuals that underwent BMT from a CCR5 wild-type donor [65, 66] . To better understand the impact of TBI and autologous hematopoietic stem cell transplant (HSCT) with HSC that were mobilized and collected prior to RT-SHIV infection, we designed and conducted a pilot study in ART-treated SHIV-infected RM. We observed that virus rebounded in 2/3 SHIV-infected, ART-treated animals that underwent HSCT, engraftment, and ART interruption, whereas the third animal was sacrificed at 2 weeks post-ART interruption with undetectable viremia, but detectable virus in lymphoid tissues [11 & ]. Together, these results and those obtained by other groups in PTM [67 & ], demonstrate that autologous HSCT can be performed in SHIV-infected animals and PTM, but the protocols used did not result in cure. This model can be further interrogated to ask critical questions regarding the pathogenesis of the apparent HIV cure achieved in the Berlin patient.
Purging the reservoir with latency reactivating agents Current HIV cure efforts are focused around the hypothesis that the latent reservoir can be disrupted and eliminated by the reactivation of latent virus. This is conceived to involve the delivery of a 'shock' signal, followed by immune-mediated clearance ('kill') of the cells expressing reactivated virus. Agents designed to reactivate latent virus [latency reversing agents (LRA)], including histone deacetylase inhibitors such as vorinostat, panobinastat, and romidepsin, and a drug used to treat alcohol addiction disulfiram. These LRAs have been used safely in HIV-infected individuals in several pilot studies with limited impact on virus reactivation and virtually no effect on the size of the virus reservoirs [68] [69] [70] [71] [72] . Ling et al. [73] and Del Prete et al. [74] tested vorinostat in ART suppressed SIV infection of Chinese and Indian RM, respectively, and obtained results similar to those of the above mentioned human clinical trials. Del Prete et al. [33 & ] have also recently used a pan histone de-acetylase inhibitor, romidepsin, to reactivate SIV infection in ARTtreated RM. When ART was interrupted, plasma virus rebound was similar in romidepsin-treated SIV-infected RM compared with non-romidepsintreated control animals. Although these initial results with LRA strategies in both preclinical NHP studies and human clinical trials have not been very impressive, there is considerable optimism in the field as novel classes of LRA are being developed and tested, including toll-like receptor agonists, and combinations of LRA with immune enhancing strategies (i.e., therapeutic vaccines, checkpoint blockade inhibitors, and monoclonal antibodies) are being explored in studies that rely heavily on the use of ART-treated SIV-infected RM.
Mapping out HIV/SIV infection in the central nervous system under ART
A subset of ART-treated HIV-infected individuals show central nervous system (CNS) symptoms that have been grouped under the term of HIV-associated neurocognitive disorder (HAND) [75] [76] [77] . However, it remains unclear to what extent the pathogenesis of HAND is due to direct virus replication in the CNS despite ART. Using ART-treated SIV-infected macaque, it was shown that SIV-DNA can be detected in the brain tissue and CSF, thus indicating that the CNS can serve as a site of SIV persistence [6,7,78,79 && ]. Although it is challenging to measure neurocognitive dysfunction in NHPs, investigations of the CNS in NHPs are particularly useful given the extreme difficulty in sampling this anatomic compartment in HIV-infected humans. As such, a number of behavioral and biological abnormalities are currently being investigated in RM as potential markers of brain dysfunction to be used for studies of the CNS reservoirs in SIV-infected ART-treated RM. Recently, Beck et al. [80 && ] showed a difference in infection efficiency of the virus infecting the CNS compared with the periphery. These authors characterized the viral fitness of both wild-type SIV and the specific CTL escape mutant (K165R) to show that the perivascular CTL response exerts selective pressure on wild-type SIV in the CNS but not in the periphery, suggesting that the virus causing CNS infection may be different from its peripheral counterpart. Furthermore, in a brief report Marcondes et al.
[79 && ] specifically depleted CD8 þ T cells in the CNS of SIV-infected RM (non-ART-treated) via intrathecal injection of CD8 þ depleting antibody and found that viral loads in the CNS were significantly higher than those observed in control groups, thus highlighting the importance of the CD8 þ T-cell response protecting the CNS from viral replication. Further studies of the CNS-based virus reservoir in ART-treated SIV-infected RM or PTM will likely identify site-specific mechanisms of virus persistence and allow the preclinical testing of novel therapeutic approaches that specifically target the CNS reservoir.
Targeting HIV/SIV persistence in the gut
The gut is a unique anatomical reservoir of HIV latency as well as a site of residual immune activation in ART-treated HIV-infected individuals [1, 2, 81, 82] . Th17 and Th22 CD4 þ T cells mediate protection against bacteria and fungi in gastrointestinal-associated lymphoid tissues but are depleted during HIV/SIV infection and fail to fully reconstitute upon ART [6, 8, 83] . Recently, Ryan et al. [15] have described a set of changes in the Th17 and Th22 frequency and function during SIV infection prior to, during and off ART treatment in blood, lymph nodes, and the colorectum. The authors found that ART failed to restore Th17 and Th22 function and frequency to pre-SIV infection levels, and that these markers were predictive of residual immune activation, SIV persistence, and signs of disease progression in the colorectum and blood. Ortiz et al. [34 && ] has shown that combination IL-21 and probiotic treatment lead to high frequencies of Th17 cells in the gut and improved gut recovery post-ART initiation in SIV-infected RM. Similarly, Micci et al. [23] showed that IL-21 alone administration to ART-treated SIV-infected RM results in enhanced recovery of Th17 and Th22 cells in the gastrointestinal tract, attenuated signs of inflammation, and reduced levels of plasma SIV RNA. Promisingly, these enhancements in the intestinal mucosal immune function remained stable through treatment interruption, suggesting that IL-21 treatment may represent a promising component of HIV cure interventions.
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